false
IDEXX LABORATORIES INC /DE
0000874716
0000874716
2024-08-06
2024-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 6, 2024
IDEXX
LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-19271 |
|
01-0393723 |
| (State
or other jurisdiction |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
| of
incorporation) |
|
|
|
|
| One IDEXX Drive, Westbrook, Maine |
|
|
|
04092 |
(Address
of principal executive offices) |
|
|
|
(ZIP
Code) |
207.556.0300
(Registrant's
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.10 par value per share |
|
IDXX |
|
NASDAQ
Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On August 6, 2024, IDEXX Laboratories, Inc. (the
“Company”) announced its financial results for the quarter ended June 30, 2024. The full text of the press release issued
in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with general instructions to Form
8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) |
Exhibits |
| |
|
| |
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
IDEXX LABORATORIES, INC. |
| |
|
| Date: August 6, 2024 |
By: |
/s/ Brian P. McKeon |
| |
|
Brian P. McKeon |
| |
|
Executive Vice President, |
| |
|
Chief Financial Officer and Treasurer |
Exhibit 99.1
| FOR IMMEDIATE RELEASE |
Contact: John Ravis, Investor Relations, 1-207-556-8155 |
IDEXX Laboratories
Announces Second Quarter Results
| · | Achieves
second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics
recurring revenue growth of 6% as reported and 7% organic. |
| · | Solid
growth supported by continued benefits from IDEXX execution drivers, including record second
quarter premium instrument placements and double-digit year-over-year global premium instrument
installed base growth. |
| · | Delivers
EPS of $2.44, a decline of 9% as reported reflecting a $62 million, $0.56 per share discrete
expense accrual related to an ongoing litigation matter. On a comparable basis, excluding
this impact, EPS increased 15%. |
| · | Updates
2024 revenue guidance to $3,885 million - $3,945 million, reflecting 6.2% - 7.8% growth as
reported and 6.2% - 7.8% organic, driven by projected CAG Diagnostics recurring revenue growth
of 5.7% - 7.3% as reported and 6.2% - 7.8% organic. |
| · | Adjusts
2024 EPS outlook to $10.31 - $10.59, a reduction of $0.56 per share at midpoint reflecting
impacts from the $0.56 per share discrete litigation expense accrual and consistent expectations
for solid comparable operating margin improvement. |
WESTBROOK, Maine, August 6,
2024— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter
results.
Second Quarter Results
The Company reports revenues of $1,004
million for the second quarter of 2024, an increase of 6% as reported and 7% organic, driven by Companion Animal Group ("CAG")
growth of 6% as reported and 7% organic, and Water revenue growth of 9% as reported and 10% organic. CAG Diagnostics recurring revenue
growth of 6% as reported and 7% organic was supported by strong growth in international regions and sustained global benefits from IDEXX
execution drivers. IDEXX veterinary software, services and diagnostic imaging systems revenue increased 12% as reported and 8% organic,
reflecting high recurring revenue growth and continued momentum in cloud-based software placements. Strong interest in IDEXX solutions
supported record second quarter premium instrument placements and 11% annual growth in IDEXX's global premium instrument installed base.
Second quarter earnings per diluted
share (“EPS”) were $2.44, a decrease of 9% as reported and an increase of 15% on a comparable basis excluding a $0.56 per
share impact related to a discrete expense accrual for an ongoing litigation matter.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 2 of 17
"Continued high levels of execution
from IDEXX teams drove solid global growth and strong operational performance in the second quarter,” said Jay Mazelsky, President
and Chief Executive Officer. “These results reflect the benefits that IDEXX customers gain from adopting our innovative, multi-modality
testing platforms and solutions. Veterinarians appreciate the deep diagnostics insights generated by IDEXX solutions, which help them
deliver better patient outcomes and seamless workflow for better business results. This value-added partnership, supported by IDEXX innovation,
sets a strong foundation for long-term growth through higher standards of pet healthcare."
Second Quarter Performance Highlights
Companion Animal Group
The Companion Animal Group generated
revenue growth of 6% as reported and 7% organic for the quarter. Solid growth was supported by CAG Diagnostics recurring revenue growth
of 6% as reported and 7% organic. CAG Diagnostics recurring revenue growth was supported by 8% reported and 10% organic gains in international
regions. U.S. CAG Diagnostics recurring revenue growth of 5% as reported and organic remained solidly above sector growth levels in the
second quarter.
Additional U.S. companion animal practice
key metrics are available in the Q2 2024 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.
Solid global growth was achieved across
IDEXX's testing modalities.
| · | IDEXX
VetLab® consumables generated 7% reported and 8% organic revenue growth,
with solid gains in the U.S. and continued double-digit organic gains internationally supported
by strong installed base growth across premium instrument platforms. |
| · | Reference
laboratory diagnostic and consulting services generated 5% reported and 6% organic revenue
growth, driven by solid U.S. gains and high single-digit organic growth in international
regions. |
| · | Rapid
assay products revenues grew 6% as reported and organic, driven by solid gains in the
U.S., supported by benefits from higher net price realization. |
Veterinary software, services and diagnostic
imaging systems revenues grew 12% as reported and 8% organically, driven by continued high levels of organic growth in software and diagnostic
imaging recurring revenues and benefits from a recent software and data platform acquisition.
Water
Water revenues grew 9% as reported and
10% organic for the quarter, reflecting strong growth in the U.S. and Europe.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 3 of 17
Livestock, Poultry and Dairy (“LPD”)
LPD revenues grew 1% as reported and
3% organically for the quarter. Solid gains in the U.S. and Europe were partially offset by lower Asia Pacific revenues, including impacts
from reduced swine testing and herd health screening levels.
Gross Profit and Operating Profit
Gross profits increased 8% as reported
and 9% on a comparable basis. Gross margin of 61.7% increased 100 basis points as reported and 90 basis points on a comparable basis,
supported by benefits from net price realization offsetting inflationary cost impacts, software service margin gains and favorable business
mix.
Operating margin was 26.3% for the quarter,
lower than the prior year by 510 basis points including ~610 basis point negative impact from $62 million of expense related to a discrete
litigation expense accrual. On a comparable basis excluding this item and foreign exchange effects, operating margins increased 110 basis
points. Operating margin results reflect 28% operating expense growth as reported and 7% on a comparable basis excluding expense related
to the discrete litigation accrual.
2024 Growth and Financial Performance
Outlook
The Company is updating its full year
revenue growth guidance range to $3,885 million to $3,945 million, or reported growth of 6.2% - 7.8%, a reduction of $15 million at midpoint.
This reflects an adjustment of ~1% at midpoint to full year estimates for organic revenue growth, which is now projected at 6.2% to 7.8%,
reflecting recent trends in U.S. clinical visit levels. The updated guidance range includes ~$15 million of favorable impact from more
recent foreign exchange estimates.
The Company updated its full year reported
operating margin outlook to reflect consistent midpoint goals for comparable operating margin improvement and to incorporate the expenses
related to an ongoing litigation matter. The Company's reported operating margin outlook is 28.7% - 29.0%, including ~160 basis points
of impact related to the discrete litigation expense accrual. At midpoint, projected full year comparable operating profit margin expansion
of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the
first quarter of 2023.
The Company updated its EPS outlook
range to $10.31 - $10.59, a reduction of $0.56 at midpoint, reflecting a $0.56 negative impact from a discrete litigation expense accrual.
Adjustments to the organic revenue outlook were offset by $0.04 in favorable adjustments to foreign exchange estimates and favorable
refinements to interest expense and effective tax rate estimates. The updated EPS growth outlook is 2% - 5% as reported and 9% - 12%
on comparable basis, including a ~2% negative growth impact from lapping a customer contract resolution payment in the first quarter
of 2023.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 4 of 17
The following table provides the Company's
updated outlook for annual key financial metrics in 2024 with a comparison to the prior outlook:
Amounts in millions except per share
data and percentages
2024 Growth and Financial Performance Outlook
| |
|
Updated |
|
Prior |
| Revenue |
|
$ 3,885 -
$ 3,945 |
|
$ 3,895 - $
3,965 |
| Reported growth |
|
6.2 % -
7.8 % |
|
6.5 % -
8.5 % |
| Organic growth |
|
6.2 % -
7.8 % |
|
7.0 % -
9.0 % |
| CAG Diagnostics Recurring Revenue Growth |
|
|
|
|
| Reported growth |
|
5.7 % -
7.3 % |
|
6.5 % -
8.5 % |
| Organic growth |
|
6.2 % -
7.8 % |
|
7.5 % -
9.5 % |
| Operating Margin |
|
28.7 % -
29.0 % |
|
30.2 % -
30.7 % |
| Operating margin
expansion |
|
(130 bps) -
(100 bps) |
|
20 bps -
70 bps |
| Negative impact of
ongoing litigation matter |
|
~160 bps |
|
|
| Comparable margin
expansion |
|
30 bps -
60 bps |
|
20 bps -
70 bps |
| Negative impact of
2023 customer contract resolution payment |
|
~ 40 bps |
|
~ 40 bps |
| EPS |
|
$ 10.31 -
$ 10.59 |
|
$ 10.82
- $ 11.20 |
| Reported growth |
|
2 % -
5 % |
|
8 % -
11 % |
| Negative impact of
ongoing litigation matter |
|
~6% |
|
|
| Comparable growth |
|
9 % -
12 % |
|
9 % -
13 % |
| Negative impact of
2023 customer contract resolution payment |
|
~2% |
|
~2% |
| Other Key Metrics |
|
|
|
|
| Net interest expense |
|
~$20 |
|
~$21 |
| Share-based compensation
tax benefit |
|
~$10 |
|
~$10 |
| Share-based compensation
tax rate benefit |
|
~1% |
|
~1% |
| Effective tax rate |
|
~21.5% |
|
~22% |
| Share-based compensation
EPS impact |
|
~$0.12 |
|
~$0.12 |
| Reduction in average
shares outstanding |
|
0.5 % - 1 % |
|
0.5 % - 1
% |
| Operating Cash Flow (% of Net Income) |
|
110% - 115% |
|
110% - 115% |
| Free Cash Flow (% of Net Income) |
|
90% - 95% |
|
90% - 95% |
| Capital Expenditures |
|
~ $180 million |
|
~ $180 million |
IDEXX Announces Second Quarter Results
August 6, 2024
Page 5 of 17
The following table outlines estimates
of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions
reflected in the above financial performance outlook for 2024.
| Estimated
Foreign Currency Exchange Rate Impacts |
|
2024 |
|
| Revenue growth rate impact |
|
(~
50 bps) |
|
| CAG Diagnostics recurring revenue
growth rate impact |
|
(~
50 bps) |
|
| Operating margin growth impact |
|
~
0 bps |
|
| EPS impact |
|
(~
$0.05) |
|
| EPS growth impact |
|
(~
1%) |
|
| Go-Forward Foreign Currency Exchange Rate Assumptions | |
2024 | |
| In U.S. dollars | |
| | |
| euro | |
$ | 1.07 | |
| British pound | |
$ | 1.26 | |
| Canadian dollar | |
$ | 0.72 | |
| Australian dollar | |
$ | 0.66 | |
| Relative to the U.S. dollar | |
| | |
| Japanese yen | |
¥ | 163 | |
| Chinese renminbi | |
¥ | 7.38 | |
| Brazilian real | |
| R$5.55 | |
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will be
hosting a conference call today at 9:00 a.m. (EDT) to discuss its second quarter 2024 results and management’s outlook. To
participate in the conference call, dial 1-800-289-0459 or 1-773-305-6837 and reference passcode 399723. Individuals can access a live
webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast
will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.
2024 Investor Day
IDEXX Laboratories, Inc. will host
its 2024 Investor Day on Thursday, August 15, 2024 from 8:00 am to approximately 12:00 pm (EDT). A live audio webcast and accompanying
slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately
one hour following the event at www.idexx.com/investors. For additional information contact investorrelations@idexx.com.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 6 of 17
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare
innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary
medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the
world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also
help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc.
is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers
solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.
IDEXX
Announces Second Quarter Results
August 6, 2024
Page 7 of 17
Note Regarding Forward-Looking Statements
This earnings release and the statements
to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation
Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial
results for future periods. Forward-looking statements are included above under "2024 Growth and Financial Performance Outlook"
and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends",
"would", "will", "plans", "believes", "estimates", "projected", "should",
and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial
performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates
and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from
share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense;
U.S. clinical visit trends; net price realization improvement; product launches; and the ongoing litigation matter. These statements
are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's
estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance.
These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels
of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk
Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations"
and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2023 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the
quarter ended March 31, 2024 and June 30, 2024, as well as those described from time to time in the Company’s other filings
with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise.
Statement Regarding Non-GAAP Financial
Measures
The following defines terms and conventions
and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call
that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"),
otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance
with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP
financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance
and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity
and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating
the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation
or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures
may not be the same as similarly titled measures reported by other companies.
Constant currency - Constant
currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent
with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency
on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions
for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts
on our effective tax rates. These estimated currency changes impacted second quarter 2024 results as follows: decreased gross profit
growth by 0.7%, increased gross margin growth by 10 basis points, decreased operating expense growth by 0.4%, decreased operating profit
growth by 0.9%, decreased operating profit margin growth by 10 basis points, and decreased EPS growth by 0.7%. Constant currency revenue
growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the
impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from
currency for the three and six months ended June 30, 2024 and refer to the 2024 Growth and Financial Performance Outlook section
of this earnings release for estimated foreign currency exchange rate impacts on 2024 projections and estimates.
Growth and organic revenue growth
- All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted.
Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue, as compared to the same period
for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures.
Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons
of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered
in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary
analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and six months ended
June 30, 2024. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please
refer to the 2024 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2024 organic revenue
growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents
revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable
to business acquisitions. Revenue from acquisitions is not expected to have benefit projected full year 2024 revenue growth by 0.5% and
have no impact on CAG Diagnostics recurring revenue growth.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 8 of 17
Comparable growth metrics - Comparable gross profit growth,
comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating
margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring
or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.
Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense
growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors
because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent
of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth,
comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating
margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth,
gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.
The reconciliation of these non-GAAP financial measures is as follows:
| | |
Three Months Ended | | |
Year-over-Year | | |
Six Months Ended | | |
Year-over-Year | |
| | |
June 30, | | |
June 30, | | |
| | |
June 30, | | |
June 30, | | |
| |
| Dollar amounts in thousands | |
2024 | | |
2023 | | |
Change | | |
2024 | | |
2023 | | |
Change | |
| Gross Profit (as reported) | |
$ | 619,159 | | |
$ | 572,850 | | |
8 | % | |
$ | 1,212,229 | | |
$ | 1,115,821 | | |
9 | % |
| Gross margin | |
| 61.7 | % | |
| 60.7 | % | |
100 bps | | |
| 61.6 | % | |
| 60.5 | % | |
110 bps | |
| Less: comparability adjustments | |
| | | |
| | | |
| | |
| | | |
| | | |
| |
| Change from currency | |
| (3,777 | ) | |
| — | | |
| | |
| (3,121 | ) | |
| — | | |
| |
| Comparable gross profit growth | |
$ | 622,936 | | |
$ | 572,850 | | |
9 | % | |
$ | 1,215,350 | | |
$ | 1,115,821 | | |
9 | % |
| Comparable gross margin and gross margin gain (or growth) | |
| 61.6 | % | |
| 60.7 | % | |
90 bps | | |
| 61.6 | % | |
| 60.5 | % | |
100 bps | |
| | |
| | | |
| | | |
| | |
| | | |
| | | |
| |
| Operating expenses (as reported) | |
$ | 355,358 | | |
$ | 276,706 | | |
28 | % | |
$ | 649,470 | | |
$ | 539,278 | | |
20 | % |
| Less: comparability adjustments | |
| | | |
| | | |
| | |
| | | |
| | | |
| |
| Change from currency | |
| (1,164 | ) | |
| — | | |
| | |
| (305 | ) | |
| — | | |
| |
| Ongoing litigation matter | |
| 61,500 | | |
| — | | |
| | |
| 61,500 | | |
| — | | |
| |
| Comparable operating expense growth | |
$ | 295,022 | | |
$ | 276,706 | | |
7 | % | |
$ | 588,275 | | |
$ | 539,278 | | |
9 | % |
| | |
| | | |
| | | |
| | |
| | | |
| | | |
| |
| Income from operations (as reported) | |
$ | 263,801 | | |
$ | 296,144 | | |
(11 | )% | |
$ | 562,759 | | |
$ | 576,543 | | |
(2 | )% |
| Operating margin | |
| 26.3 | % | |
| 31.4 | % | |
(510) bps | | |
| 28.6 | % | |
| 31.3 | % | |
(270) bps | |
| Less: comparability adjustments | |
| | | |
| | | |
| | |
| | | |
| | | |
| |
| Change from currency | |
| (2,613 | ) | |
| — | | |
| | |
| (2,816 | ) | |
| — | | |
| |
| Ongoing litigation matter | |
| (61,500 | ) | |
| — | | |
| | |
| (61,500 | ) | |
| — | | |
| |
| Comparable operating profit growth | |
$ | 327,914 | | |
$ | 296,144 | | |
11 | % | |
$ | 627,075 | | |
$ | 576,543 | | |
9 | % |
| Comparable operating margin and operating margin gain (or growth) | |
| 32.4 | % | |
| 31.4 | % | |
110 bps | | |
| 31.8 | % | |
| 31.3 | % | |
50 bps | |
Amounts presented may not recalculate due to rounding.
Projected 2024 comparable operating margin expansion outlined in the
2024 Growth and Financial Performance Outlook section of this earnings release reflects: (i) projected full year 2024 reported operating
margin is adjusted for impacts of the discrete expense accrual related to an ongoing litigation matter in the second quarter of 2024;
and (ii) projected full year 2024 reported operating margin includes an immaterial impact from year-over-year foreign currency exchange
rate changes at noted exchange rates.
These impacts described above reconcile reported gross profit growth,
gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2024 operating margin
expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating
profit growth and comparable operating margin gain for the Company.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 9 of 17
Comparable EPS growth - Comparable EPS growth is a non-GAAP
financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as
compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding
the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements
to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth
is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period
comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency
to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement
of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary
of foreign currency exchange rate impacts.
The reconciliation of this non-GAAP financial measure is as follows:
| | |
Three Months Ended | |
Year-over-Year | | |
Six Months Ended | |
Year-over-Year | |
| | |
June 30, | |
June 30, | |
| | |
June 30, | |
June 30, | |
| |
| | |
2024 | |
2023 | |
Growth | | |
2024 | |
2023 | |
Growth | |
| Earnings per share (diluted) | |
$ | 2.44 | |
$ | 2.67 | |
(9 | )% | |
$ | 5.24 | |
$ | 5.22 | |
— | % |
| Less: comparability adjustments | |
| | |
| | |
| | |
| | |
| | |
| |
| Share-based compensation activity | |
| 0.00 | |
| 0.04 | |
| | |
| 0.10 | |
| 0.10 | |
| |
| Ongoing litigation matter | |
| (0.56 | ) |
| — | |
| | |
| (0.56 | ) |
| — | |
| |
| Change from currency | |
| (0.02 | ) |
| — | |
| | |
| (0.03 | ) |
| — | |
| |
| Comparable EPS growth | |
| 3.02 | |
| 2.63 | |
15 | % | |
| 5.73 | |
| 5.12 | |
12 | % |
Amounts presented may not recalculate due to rounding.
Projected 2024 comparable EPS growth outlined in the 2024 Growth and
Financial Performance Outlook section of this earnings release reflects adjustments to projected full year 2024 reported EPS for: (i) estimated
positive share-based compensation activity of ~$0.12; (ii) a negative $0.56 impact from a discrete expense accrual related to an
ongoing litigation matter in the second quarter of 2024; and (iii) estimated negative year-over-year foreign currency exchange rate
change impact of ~$0.05 at noted exchange rates.
These impacts and those described in the constant currency note above
reconcile reported EPS growth (including projected 2024 reported EPS growth) to comparable EPS growth for the Company.
Free cash flow - Free cash flow is a non-GAAP financial measure
and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s
investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations
of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to
operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash
provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three
and six months ended June 30, 2024 and 2023. To estimate projected 2024 free cash flow, we have deducted projected purchases of
property and equipment (also referred to as capital expenditures) of approximately $180. Free cash flow conversion, or the net income
to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided
by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended
June 30, 2024, we have deducted purchases of property and equipment of approximately $130 million from net cash provided from operating
activities of approximately $969 million, divided by net income of approximately $846 million.
Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted
EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before
interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions,
share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA,
gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the
Company's business performance and available borrowing capacity under the
Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of
or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA
and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended
December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 10 of 17
Notes and Definitions
Discrete litigation expense accrual - During the second quarter
of 2024, the Company increased its previously established $27.5 million accrual related to an ongoing litigation matter by $61.5 million.
Ongoing litigation matter - The Company is a defendant in an
ongoing litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under
an expired patent license agreement. The Company's total accrual of $89.0 million for this matter includes the discrete $61.5 million
litigation expense accrual recorded in the second quarter of 2024 and represents our best estimate of the amount of the probable loss.
The actual loss associated with this matter may be higher or lower than the accrued amount depending on the ultimate outcome of this
matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 11 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
| | |
| |
Three Months Ended | |
Six Months Ended | |
| | |
| |
June 30, | |
June 30, | |
June 30, | |
June 30, | |
| | |
| |
2024 | |
2023 | |
2024 | |
2023 | |
| Revenue: | |
Revenue | |
$ | 1,003,578 | |
$ | 943,630 | |
$ | 1,967,673 | |
$ | 1,843,825 | |
| Expenses and Income: | |
Cost of revenue | |
| 384,419 | |
| 370,780 | |
| 755,444 | |
| 728,004 | |
| | |
Gross profit | |
| 619,159 | |
| 572,850 | |
| 1,212,229 | |
| 1,115,821 | |
| | |
Sales and marketing | |
| 142,665 | |
| 140,532 | |
| 292,118 | |
| 288,336 | |
| | |
General and administrative | |
| 157,243 | |
| 89,669 | |
| 249,267 | |
| 159,770 | |
| | |
Research and development | |
| 55,450 | |
| 46,505 | |
| 108,085 | |
| 91,172 | |
| | |
Income from operations | |
| 263,801 | |
| 296,144 | |
| 562,759 | |
| 576,543 | |
| | |
Interest expense, net | |
| (4,745 | ) |
| (10,215 | ) |
| (8,224 | ) |
| (22,926 | ) |
| | |
Income before provision for income taxes | |
| 259,056 | |
| 285,929 | |
| 554,535 | |
| 553,617 | |
| | |
Provision for income taxes | |
| 55,758 | |
| 61,693 | |
| 115,658 | |
| 115,327 | |
| Net Income: | |
Net income attributable to stockholders | |
$ | 203,298 | |
$ | 224,236 | |
$ | 438,877 | |
$ | 438,290 | |
| | |
Earnings per share: Basic | |
$ | 2.46 | |
$ | 2.70 | |
$ | 5.30 | |
$ | 5.28 | |
| | |
Earnings per share: Diluted | |
$ | 2.44 | |
$ | 2.67 | |
$ | 5.24 | |
$ | 5.22 | |
| | |
Shares outstanding: Basic | |
| 82,630 | |
| 83,086 | |
| 82,863 | |
| 83,039 | |
| | |
Shares outstanding: Diluted | |
| 83,393 | |
| 83,983 | |
| 83,684 | |
| 83,980 | |
IDEXX Laboratories, Inc. and Subsidiaries
Selected
Operating Information (Unaudited)
| | |
| |
Three Months Ended | | |
Six Months Ended | |
| | |
| |
June 30, | | |
June 30, | | |
June 30, | | |
June 30, | |
| | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| Operating Ratios | |
Gross profit | |
61.7 | % | |
60.7 | % | |
61.6 | % | |
60.5 | % |
| (as a percentage of revenue): | |
Sales, marketing, general and administrative expense | |
29.9 | % | |
24.4 | % | |
27.5 | % | |
24.3 | % |
| | |
Research and development expense | |
5.5 | % | |
4.9 | % | |
5.5 | % | |
4.9 | % |
| | |
Income from operations1 | |
26.3 | % | |
31.4 | % | |
28.6 | % | |
31.3 | % |
1Amounts presented may not recalculate due to rounding.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 12 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)
| | |
| |
Three Months Ended | |
| | |
| |
June 30, 2024 | |
Percent of Revenue | | |
June 30, 2023 | |
Percent of Revenue | |
| Revenue: | |
CAG | |
$ | 922,298 | |
| | |
$ | 866,652 | |
| |
| | |
Water | |
| 46,726 | |
| | |
| 43,029 | |
| |
| | |
LPD | |
| 30,306 | |
| | |
| 29,911 | |
| |
| | |
Other | |
| 4,248 | |
| | |
| 4,038 | |
| |
| | |
Total | |
$ | 1,003,578 | |
| | |
$ | 943,630 | |
| |
| | |
| |
| | |
| | |
| | |
| |
| Gross Profit: | |
CAG | |
$ | 569,071 | |
61.7 | % | |
$ | 525,709 | |
60.7 | % |
| | |
Water | |
| 32,074 | |
68.6 | % | |
| 30,319 | |
70.5 | % |
| | |
LPD | |
| 15,558 | |
51.3 | % | |
| 16,086 | |
53.8 | % |
| | |
Other | |
| 2,456 | |
57.8 | % | |
| 736 | |
18.2 | % |
| | |
Total | |
$ | 619,159 | |
61.7 | % | |
$ | 572,850 | |
60.7 | % |
| | |
| |
| | |
| | |
| | |
| |
| Income from Operations: | |
CAG | |
$ | 241,550 | |
26.2 | % | |
$ | 275,509 | |
31.8 | % |
| | |
Water | |
| 20,504 | |
43.9 | % | |
| 19,820 | |
46.1 | % |
| | |
LPD | |
| 1,499 | |
4.9 | % | |
| 1,951 | |
6.5 | % |
| | |
Other | |
| 248 | |
5.8 | % | |
| (1,136 | ) |
(28.1 | )% |
| | |
Total | |
$ | 263,801 | |
26.3 | % | |
$ | 296,144 | |
31.4 | % |
| | |
| |
Six Months Ended | |
| | |
| |
June 30, 2024 | |
Percent of Revenue | | |
June 30, 2023 | |
Percent of Revenue | |
| Revenue: | |
CAG | |
$ | 1,811,583 | |
| | |
$ | 1,693,931 | |
| |
| | |
Water | |
| 89,797 | |
| | |
| 81,912 | |
| |
| | |
LPD | |
| 58,511 | |
| | |
| 59,119 | |
| |
| | |
Other | |
| 7,782 | |
| | |
| 8,863 | |
| |
| | |
Total | |
$ | 1,967,673 | |
| | |
$ | 1,843,825 | |
| |
| | |
| |
| | |
| | |
| | |
| |
| Gross Profit: | |
CAG | |
$ | 1,115,307 | |
61.6 | % | |
$ | 1,024,466 | |
60.5 | % |
| | |
Water | |
| 62,571 | |
69.7 | % | |
| 57,587 | |
70.3 | % |
| | |
LPD | |
| 30,792 | |
52.6 | % | |
| 31,139 | |
52.7 | % |
| | |
Other | |
| 3,559 | |
45.7 | % | |
| 2,629 | |
29.7 | % |
| | |
Total | |
$ | 1,212,229 | |
61.6 | % | |
$ | 1,115,821 | |
60.5 | % |
| | |
| |
| | |
| | |
| | |
| |
| Income from Operations: | |
CAG | |
$ | 521,246 | |
28.8 | % | |
$ | 537,259 | |
31.7 | % |
| | |
Water | |
| 39,934 | |
44.5 | % | |
| 36,791 | |
44.9 | % |
| | |
LPD | |
| 2,365 | |
4.0 | % | |
| 3,259 | |
5.5 | % |
| | |
Other | |
| (786 | ) |
(10.1 | )% | |
| (766 | ) |
(8.6 | )% |
| | |
Total | |
$ | 562,759 | |
28.6 | % | |
$ | 576,543 | |
31.3 | % |
IDEXX Announces Second Quarter Results
August 6, 2024
Page 13 of 17
| IDEXX Laboratories, Inc. and Subsidiaries |
| Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets |
| Amounts in thousands (Unaudited) |
| | |
Three Months Ended | | |
Dollar | | |
Reported
Revenue | | |
Percentage
Change from | | |
Percentage
Change from | | |
Organic
Revenue | |
| Net Revenue | |
June 30, 2024 | | |
June 30, 2023 | | |
Change | | |
Growth1 | | |
Currency | | |
Acquisitions | | |
Growth1 | |
| CAG | |
$ | 922,298 | | |
$ | 866,652 | | |
$ | 55,646 | | |
| 6.4 | % | |
| (0.7 | )% | |
| 0.4 | % | |
| 6.7 | % |
| United States | |
| 628,684 | | |
| 594,395 | | |
| 34,289 | | |
| 5.8 | % | |
| — | | |
| 0.5 | % | |
| 5.2 | % |
| International | |
| 293,614 | | |
| 272,257 | | |
| 21,357 | | |
| 7.8 | % | |
| (2.2 | )% | |
| — | | |
| 10.1 | % |
| Water | |
| 46,726 | | |
| 43,029 | | |
| 3,697 | | |
| 8.6 | % | |
| (0.9 | )% | |
| — | | |
| 9.5 | % |
| United States | |
| 24,461 | | |
| 21,208 | | |
| 3,253 | | |
| 15.3 | % | |
| — | | |
| — | | |
| 15.3 | % |
| International | |
| 22,265 | | |
| 21,821 | | |
| 444 | | |
| 2.0 | % | |
| (1.8 | )% | |
| — | | |
| 3.8 | % |
| LPD | |
| 30,306 | | |
| 29,911 | | |
| 395 | | |
| 1.3 | % | |
| (1.6 | )% | |
| — | | |
| 2.9 | % |
| United States | |
| 5,115 | | |
| 4,422 | | |
| 693 | | |
| 15.7 | % | |
| — | | |
| — | | |
| 15.7 | % |
| International | |
| 25,191 | | |
| 25,489 | | |
| (298 | ) | |
| (1.2 | )% | |
| (1.8 | )% | |
| — | | |
| 0.7 | % |
| Other | |
| 4,248 | | |
| 4,038 | | |
| 210 | | |
| 5.2 | % | |
| — | | |
| — | | |
| 5.2 | % |
| Total Company | |
$ | 1,003,578 | | |
$ | 943,630 | | |
$ | 59,948 | | |
| 6.4 | % | |
| (0.7 | )% | |
| 0.3 | % | |
| 6.7 | % |
| United States | |
| 660,146 | | |
| 621,607 | | |
| 38,539 | | |
| 6.2 | % | |
| — | | |
| 0.5 | % | |
| 5.7 | % |
| International | |
| 343,432 | | |
| 322,023 | | |
| 21,409 | | |
| 6.6 | % | |
| (2.1 | )% | |
| — | | |
| 8.8 | % |
| | |
Three Months Ended | |
Dollar | | |
Reported
Revenue | | |
Percentage
Change from | | |
Percentage
Change from | | |
Organic
Revenue | |
| Net CAG Revenue | |
June 30, 2024 | |
June 30, 2023 | |
Change | | |
Growth1 | | |
Currency | | |
Acquisitions | | |
Growth1 | |
| CAG Diagnostics recurring revenue: | |
$ | 808,454 | |
$ | 762,476 | |
$ | 45,978 | | |
6.0 | % | |
(0.7 | )% | |
— | | |
6.7 | % |
| IDEXX VetLab consumables | |
| 325,348 | |
| 303,735 | |
| 21,613 | | |
7.1 | % | |
(1.0 | )% | |
— | | |
8.1 | % |
| Rapid assay products | |
| 103,290 | |
| 97,340 | |
| 5,950 | | |
6.1 | % | |
(0.4 | )% | |
— | | |
6.5 | % |
| Reference laboratory diagnostic and consulting services | |
| 347,373 | |
| 330,106 | |
| 17,267 | | |
5.2 | % | |
(0.5 | )% | |
— | | |
5.8 | % |
| CAG Diagnostics services and accessories | |
| 32,443 | |
| 31,295 | |
| 1,148 | | |
3.7 | % | |
(1.0 | )% | |
— | | |
4.7 | % |
| CAG Diagnostics capital – instruments | |
| 35,292 | |
| 34,054 | |
| 1,238 | | |
3.6 | % | |
(1.2 | )% | |
— | | |
4.8 | % |
| Veterinary software, services and diagnostic imaging systems: | |
| 78,552 | |
| 70,122 | |
| 8,430 | | |
12.0 | % | |
(0.1 | )% | |
4.5 | % | |
7.6 | % |
| Recurring revenue | |
| 63,117 | |
| 53,725 | |
| 9,392 | | |
17.5 | % | |
(0.1 | )% | |
5.9 | % | |
11.7 | % |
| Systems and hardware | |
| 15,435 | |
| 16,397 | |
| (962 | ) | |
(5.9 | )% | |
(0.1 | )% | |
— | | |
(5.8 | )% |
| Net CAG revenue | |
$ | 922,298 | |
$ | 866,652 | |
$ | 55,646 | | |
6.4 | % | |
(0.7 | )% | |
0.4 | % | |
6.7 | % |
| | |
Three
Months Ended | |
Dollar | |
Reported
Revenue | |
Percentage
Change from | |
Percentage
Change from | |
Organic
Revenue | |
| | |
June 30, 2024 | |
June 30, 2023 | |
Change | |
Growth1 | |
Currency | |
Acquisitions | |
Growth1 | |
| CAG Diagnostics recurring revenue: | |
$ | 808,454 | |
$ | 762,476 | |
$ | 45,978 | |
6.0 | % |
(0.7 | )% |
— | |
6.7 | % |
| United States | |
| 544,466 | |
| 517,388 | |
| 27,078 | |
5.2 | % |
— | |
— | |
5.2 | % |
| International | |
| 263,988 | |
| 245,088 | |
| 18,900 | |
7.7 | % |
(2.2 | )% |
— | |
10.0 | % |
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 14 of 17
| IDEXX Laboratories, Inc. and Subsidiaries |
| Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets |
| Amounts in thousands (Unaudited) |
| | |
Six Months Ended | |
Dollar | | |
Reported
Revenue | | |
Percentage
Change from | | |
Percentage
Change from | | |
Organic
Revenue | |
| Net
Revenue | |
June 30, 2024 | |
June 30, 2023 | |
Change | | |
Growth1 | | |
Currency | | |
Acquisitions | | |
Growth1 | |
| CAG | |
$ | 1,811,583 | |
$ | 1,693,931 | |
$ | 117,652 | | |
6.9 | % | |
(0.3 | )% | |
0.3 | % | |
7.0 | % |
| United States | |
| 1,230,879 | |
| 1,158,922 | |
| 71,957 | | |
6.2 | % | |
— | | |
0.5 | % | |
5.7 | % |
| International | |
| 580,704 | |
| 535,009 | |
| 45,695 | | |
8.5 | % | |
(1.1 | )% | |
— | | |
9.7 | % |
| Water | |
| 89,797 | |
| 81,912 | |
| 7,885 | | |
9.6 | % | |
(0.4 | )% | |
— | | |
10.0 | % |
| United States | |
| 46,660 | |
| 41,128 | |
| 5,532 | | |
13.5 | % | |
— | | |
— | | |
13.5 | % |
| International | |
| 43,137 | |
| 40,784 | |
| 2,353 | | |
5.8 | % | |
(0.8 | )% | |
— | | |
6.6 | % |
| LPD | |
| 58,511 | |
| 59,119 | |
| (608 | ) | |
(1.0 | )% | |
(0.8 | )% | |
— | | |
(0.2 | )% |
| United States | |
| 10,279 | |
| 8,965 | |
| 1,314 | | |
14.7 | % | |
— | | |
— | | |
14.7 | % |
| International | |
| 48,232 | |
| 50,154 | |
| (1,922 | ) | |
(3.8 | )% | |
(1.0 | )% | |
— | | |
(2.9 | )% |
| Other | |
| 7,782 | |
| 8,863 | |
| (1,081 | ) | |
(12.2 | )% | |
— | | |
— | | |
(12.2 | )% |
| Total Company | |
$ | 1,967,673 | |
$ | 1,843,825 | |
$ | 123,848 | | |
6.7 | % | |
(0.4 | )% | |
0.3 | % | |
6.8 | % |
| United States | |
| 1,291,155 | |
| 1,212,020 | |
| 79,135 | | |
6.5 | % | |
— | | |
0.4 | % | |
6.1 | % |
| International | |
| 676,518 | |
| 631,805 | |
| 44,713 | | |
7.1 | % | |
(1.1 | )% | |
— | | |
8.1 | % |
| |
|
Six Months Ended |
|
Dollar |
|
|
Reported
Revenue |
|
|
Percentage
Change from |
|
|
Percentage
Change from |
|
|
Organic
Revenue |
|
| Net CAG Revenue |
|
June 30, 2024 |
|
June 30, 2023 |
|
Change |
|
|
Growth1 |
|
|
Currency |
|
|
Acquisitions |
|
|
Growth1 |
|
| CAG Diagnostics recurring revenue: |
|
$ |
1,588,598 |
|
$ |
1,489,378 |
|
$ |
99,220 |
|
|
6.7 |
% |
|
(0.3 |
)% |
|
— |
|
|
7.0 |
% |
| IDEXX VetLab consumables |
|
|
642,277 |
|
|
594,849 |
|
|
47,428 |
|
|
8.0 |
% |
|
(0.5 |
)% |
|
— |
|
|
8.5 |
% |
| Rapid assay products |
|
|
189,605 |
|
|
179,372 |
|
|
10,233 |
|
|
5.7 |
% |
|
(0.2 |
)% |
|
— |
|
|
5.9 |
% |
| Reference laboratory diagnostic and consulting services |
|
|
691,711 |
|
|
653,286 |
|
|
38,425 |
|
|
5.9 |
% |
|
(0.2 |
)% |
|
— |
|
|
6.1 |
% |
| CAG Diagnostics services and accessories |
|
|
65,005 |
|
|
61,871 |
|
|
3,134 |
|
|
5.1 |
% |
|
(0.7 |
)% |
|
— |
|
|
5.7 |
% |
| CAG Diagnostics capital – instruments |
|
|
69,384 |
|
|
67,198 |
|
|
2,186 |
|
|
3.3 |
% |
|
(0.8 |
)% |
|
— |
|
|
4.0 |
% |
| Veterinary software, services and diagnostic imaging systems: |
|
|
153,601 |
|
|
137,355 |
|
|
16,246 |
|
|
11.8 |
% |
|
(0.1 |
)% |
|
3.9 |
% |
|
8.0 |
% |
| Recurring revenue |
|
|
122,817 |
|
|
105,432 |
|
|
17,385 |
|
|
16.5 |
% |
|
(0.1 |
)% |
|
5.1 |
% |
|
11.5 |
% |
| Systems and hardware |
|
|
30,784 |
|
|
31,923 |
|
|
(1,139 |
) |
|
(3.6 |
)% |
|
(0.1 |
)% |
|
— |
|
|
(3.5 |
)% |
| Net CAG revenue |
|
$ |
1,811,583 |
|
$ |
1,693,931 |
|
$ |
117,652 |
|
|
6.9 |
% |
|
(0.3 |
)% |
|
0.3 |
% |
|
7.0 |
% |
| | |
Six Months Ended | |
Dollar | | |
Reported
Revenue | | |
Percentage
Change from | | |
Percentage
Change from | | |
Organic
Revenue | |
| | |
June 30, 2024 | |
June 30, 2023 | |
Change | | |
Growth1 | | |
Currency | | |
Acquisitions | | |
Growth1 | |
| CAG Diagnostics recurring revenue: | |
$ | 1,588,598 | |
$ | 1,489,378 | |
$ | 99,220 | | |
6.7 | % | |
(0.3 | )% | |
— | | |
7.0 | % |
| United States | |
| 1,067,507 | |
| 1,008,728 | |
| 58,779 | | |
5.8 | % | |
— | | |
— | | |
5.8 | % |
| International | |
| 521,091 | |
| 480,650 | |
| 40,441 | | |
8.4 | % | |
(1.1 | )% | |
— | | |
9.5 | % |
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 15 of 17
| IDEXX Laboratories, Inc. and Subsidiaries |
| Condensed Consolidated Balance Sheet |
| Amounts in thousands (Unaudited) |
| | |
| |
June 30, 2024 | | |
December 31,
2023 |
|
| Assets: | |
Current Assets: | |
| | |
|
|
|
| | |
Cash and cash equivalents | |
$ | 401,590 | | |
$453,932 |
|
| | |
Accounts receivable, net | |
| 533,606 | | |
457,445 |
|
| | |
Inventories | |
| 379,958 | | |
380,282 |
|
| | |
Other current assets | |
| 213,458 | | |
203,595 |
|
| | |
Total current assets | |
| 1,528,612 | | |
1,495,254 |
|
| | |
Property and equipment, net | |
| 708,178 | | |
702,177 |
|
| | |
Other long-term assets, net | |
| 1,178,077 | | |
1,062,494 |
|
| | |
Total assets | |
$ | 3,414,867 | | |
$3,259,925 |
|
| Liabilities and Stockholders' | |
| |
| | |
|
|
|
| Equity: | |
Current Liabilities: | |
| | |
|
|
|
| | |
Accounts payable | |
$ | 117,468 | | |
$110,643 |
|
| | |
Accrued liabilities | |
| 541,124 | | |
478,712 |
|
| | |
Line of credit | |
| 250,000 | | |
250,000 |
|
| | |
Current portion of long-term debt | |
| 170,112 | | |
74,997 |
|
| | |
Deferred revenue | |
| 37,998 | | |
37,195 |
|
| | |
Total current liabilities | |
| 1,116,702 | | |
951,547 |
|
| | |
Long-term debt, net of current portion | |
| 524,743 | | |
622,883 |
|
| | |
Other long-term liabilities, net | |
| 193,169 | | |
200,965 |
|
| | |
Total long-term liabilities | |
| 717,912 | | |
823,848 |
|
| | |
Total stockholders' equity | |
| 1,580,253 | | |
1,484,530 |
|
| | |
Total liabilities and stockholders' equity | |
$ | 3,414,867 | | |
$3,259,925 |
|
| IDEXX Laboratories, Inc. and Subsidiaries |
| |
| Selected Balance Sheet Information (Unaudited) |
| | |
| |
June 30,
2024 | | |
March 31,
2024 | | |
December 31,
2023 | | |
September 30,
2023 | | |
June 30,
2023 | |
| Selected Balance Sheet Information: | |
Days sales outstanding1 | |
| 47.3 | | |
| 45.7 | | |
| 46.1 | | |
| 45.6 | | |
| 43.9 | |
| | |
Inventory turns2 | |
| 1.4 | | |
| 1.3 | | |
| 1.3 | | |
| 1.3 | | |
| 1.3 | |
1Days sales outstanding represents
the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result
of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the ratio of four times our inventory-related cost of product revenue for the quarter, divided by the average inventory balances at the beginning and end of each quarter.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 16 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
| | |
| |
Six Months Ended |
|
| | |
| |
June 30, 2024 | | June 30, 2023 |
|
| Operating: | |
Cash Flows from Operating Activities: | |
| | |
|
|
|
| | |
Net income | |
$ | 438,877 | | $ |
438,290 |
|
| | |
Non-cash adjustments to net income | |
| 75,155 | | |
76,246 |
|
| | |
Changes in assets and liabilities | |
| (67,135 | ) | |
(130,310) |
|
| | |
Net cash provided by operating activities | |
| 446,897 | | |
384,226 |
|
| Investing: | |
Cash Flows from Investing Activities: | |
| | |
|
|
|
| | |
Purchases of property and equipment | |
| (63,578 | ) | |
(66,981) |
|
| | |
Acquisition of a business | |
| (77,000 | ) | |
— |
|
| | |
Proceeds from net investment hedges | |
| 727 | | |
— |
|
| | |
Net cash used by investing activities | |
| (139,851 | ) | |
(66,981) |
|
| Financing: | |
Cash Flows from Financing Activities: | |
| | |
|
|
|
| | |
Repayments under credit facility, net | |
| — | | |
(315,000) |
|
| | |
Payments for the acquisition-related holdbacks | |
| — | | |
(1,780) |
|
| | |
Repurchases of common stock | |
| (370,285 | ) | |
— |
|
| | |
Proceeds from exercises of stock options and employee stock purchase plans | |
| 26,241 | | |
23,086 |
|
| | |
Shares withheld for statutory tax withholding payments on restricted stock | |
| (10,268 | ) | |
(9,676) |
|
| | |
Other | |
| — | | |
6,256 |
|
| | |
Net cash used by financing activities | |
| (354,312 | ) | |
(297,114) |
|
| | |
Net effect of changes in exchange rates on cash | |
| (5,076 | ) | |
161 |
|
| | |
Net (decrease) increase in cash and cash equivalents | |
| (52,342 | ) | |
20,292 |
|
| | |
Cash and cash equivalents, beginning of period | |
| 453,932 | | |
112,546 |
|
| | |
Cash and cash equivalents, end of period | |
$ | 401,590 | | $ |
132,838 |
|
IDEXX
Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
| | |
| |
Three Months Ended | | |
Six Months Ended | |
| | |
| |
June 30, 2024 | | |
June 30, 2023 | | |
June 30, 2024 | | |
June 30, 2023 | |
| Free Cash Flow: | |
Net cash provided by operating activities | |
$ | 248,312 | | |
$ | 200,314 | | |
$ | 446,897 | | |
$ | 384,226 | |
| | |
Investing cash flows attributable to purchases of property and equipment | |
| (33,305 | ) | |
| (27,470 | ) | |
| (63,578 | ) | |
| (66,981 | ) |
| | |
Free cash flow1 | |
$ | 215,007 | | |
$ | 172,844 | | |
$ | 383,319 | | |
$ | 317,245 | |
1See Statements Regarding Non-GAAP Financial Measures, above.
IDEXX Announces Second Quarter Results
August 6, 2024
Page 17 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, 2024 | | |
June 30, 2023 | | |
June 30, 2024 | | |
June 30, 2023 | |
| Shares repurchased in the open market | |
| 415 | | |
| — | | |
| 718 | | |
| — | |
| Shares acquired through employee surrender for statutory tax withholding | |
| — | | |
| — | | |
| 18 | | |
| 19 | |
| Total shares repurchased | |
| 415 | | |
| — | | |
| 736 | | |
| 19 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost of shares repurchased in the open market | |
$ | 208,169 | | |
$ | — | | |
$ | 375,271 | | |
$ | — | |
| Cost of shares for employee surrenders | |
| 79 | | |
| 79 | | |
| 10,268 | | |
| 9,676 | |
| Total cost of shares | |
$ | 208,248 | | |
$ | 79 | | |
$ | 385,539 | | |
$ | 9,676 | |
| | |
| | | |
| | | |
| | | |
| | |
| Average cost per share – open market repurchases | |
$ | 501.44 | | |
$ | — | | |
$ | 522.32 | | |
$ | — | |
| Average cost per share – employee surrenders | |
$ | 496.95 | | |
$ | 469.84 | | |
$ | 560.01 | | |
$ | 503.35 | |
| Average cost per share – total | |
$ | 501.44 | | |
$ | 469.84 | | |
$ | 523.26 | | |
$ | 503.35 | |
v3.24.2.u1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Nov 2023 a Nov 2024
